Table 2

Univariate analysis of factors potentially associated with grade III-IV aGVHD in 106 DCBT recipients

VariableNDay 180 grade III-IV aGVHD, % (95% CI)P
Age, y    
 0-15 14 21 (5-46) .921 
 ≥16 92 21 (13-30)  
Conditioning    
 Myeloablative 80 20 (12-29) .764 
 Nonmyeloablative 26 23 (9-41)  
Infused total CD3+cell dose    
 ≤7.74 × 106/kg 55 26 (15-38) .170 
 >7.74 × 106/kg 51 16 (7-27)  
Dominant unit-recipient 6 allele HLA match    
 Worse HLA match: 2-3/6 28 32 (16-50) .077 
 Better HLA match: 4-6/6 78 17 (9-26)  
ST2 level, ng/mL    
 Low: ≤33.9 56 13 (5-23) .024 
 High: >33.9 50 30% (18-43)  
VariableNDay 180 grade III-IV aGVHD, % (95% CI)P
Age, y    
 0-15 14 21 (5-46) .921 
 ≥16 92 21 (13-30)  
Conditioning    
 Myeloablative 80 20 (12-29) .764 
 Nonmyeloablative 26 23 (9-41)  
Infused total CD3+cell dose    
 ≤7.74 × 106/kg 55 26 (15-38) .170 
 >7.74 × 106/kg 51 16 (7-27)  
Dominant unit-recipient 6 allele HLA match    
 Worse HLA match: 2-3/6 28 32 (16-50) .077 
 Better HLA match: 4-6/6 78 17 (9-26)  
ST2 level, ng/mL    
 Low: ≤33.9 56 13 (5-23) .024 
 High: >33.9 50 30% (18-43)  
Close Modal

or Create an Account

Close Modal
Close Modal